| ||||||||||||||||||||||
| ||||||||||||||||||||||
|
STOCKS |
SanDisk, the NAND flash storage maker, used Thursday’s investor day to forecast durable AI-driven growth through fiscal 2030. Management paired mid-to-high-teens revenue growth with unusually rich margin and cash-return targets, sending shares sharply higher. |
The RIP: $SNDK ( ▲ 13.67% ) +13.7% to $1,528.11on 21.7M shares. Fiscal 2028 to 2030 targets include roughly 80% adjusted gross margin, 75% adjusted operating margin, 50% adjusted free-cash-flow margin, and 100% of excess cash returned after investment. |
“Our confidence in the sustainability of the model comes from our multi-year NBMs that are based on intimate relationships with our customers and grounded in innovation and collaboration,” CFO Luis Visoso said in a statement reported by MarketWatch. |
Memory investors care because eight multiyear customer agreements already cover about half of SanDisk’s fiscal 2027 output and two-thirds in fiscal 2028, challenging the idea that current pricing is purely cyclical. @randomaccount3 sees $1,700+after any profit-taking, but the measurable test is whether those contracts preserve roughly 80% gross margins as supply and pricing normalize. |
The Community Read: The $SNDK room is bullish on 2030 targets, test the margin math -> |
POPS & DROPS | |
$TSSI -27% | TSS: The margin pivot could not hide one number | |
6.1K WATCHERS · 75% BULLISH · NORMAL ACTIVITY | |
TSS said quarterly revenue fell 20% to $35.1M as lower-margin procurement sales dropped 45%, overshadowing 46% growth in systems integration and a 12% adjusted EBITDA gain. The bullish room must decide whether the selloff mispriced a better business mix or exposed how much growth still depends on one major customer. | |
$VCX +21% | Fundrise Innovation Fund: The supply test starts Friday | |
6.9K WATCHERS · 65% BULLISH · NORMAL ACTIVITY | |
Fundrise Innovation Fund surged before previously restricted shares become eligible to trade Friday, one month earlier than originally planned. With the fund still trading above its underlying asset value, the community is split over whether exposure to SpaceX and Anthropic can absorb incoming supply without another premium reset. | |
$CADL +7% | Candel: Bulls circled one regulatory checkpoint | |
10K WATCHERS · 78% BULLISH · NORMAL ACTIVITY | |
Candel climbed without a fresh company release as traders returned to its planned fourth-quarter biologics license application for prostate cancer therapy CAN-2409. The next argument is whether manufacturing readiness has sufficiently reduced filing risk or whether partnership and buyout hopes are getting ahead of the FDA process. | |
|
WHAT’S ON DECK |
Macro: Retail sales (8:30 AM ET), Business inventories (10:00 AM ET), University of Michigan Consumer Sentiment Index (preliminary) (10:00 AM ET). |




